Harnessing oncolytic virus-mediated immunity

Frontiers Research Topics

Philippe Fournier ; Volker Schirrmacher

keywords: oncolytic virus;    anti-tumor activity;    tumor-associated antigen;    oncolytic virotherapy;    immunovirotherapy;    immunotherapeutic approaches;    anti-viral response;   

Publisher: Frontiers Media SA

Subject:

【 摘 要 】

Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity.

【 授权许可】

CC BY   
Copyright 2007-2040 Frontiers Media SA. All rights reserved. All content included on this site, such as text, graphics, logos, button icons, images, video/audio clips, downloads, data compilations and software, is the property of or is licensed to.All copyright, and all rights therein, are protected by national and internation.The above represents a summary only. For the full conditions see the Conditions for Authors and the Conditions for Website Use.

【 图 表 】

Harnessing oncolytic virus-mediated immunity.PDF

Harnessing oncolytic virus-mediated immunity.jpg